Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure

Am J Gastroenterol. 2020 Feb;115(2):179-189. doi: 10.14309/ajg.0000000000000437.

Abstract

In recent years, the therapeutic goals in ulcerative colitis (UC) have become increasingly stringent. Histological features seem to be a reliable predictor of disease outcomes after therapy, and histological remission (HR) is the new frontier in the treatment of UC. Here, we first provide a historical perspective before reviewing indexes in the era of biologics; histology as a treatment goal in UC trials; the poor correlation between symptoms, endoscopy, and histology; and the impact of histology on disease outcomes. HR seems to be a promising end point for the treatment of UC because it is typically associated with better outcomes. Two new validated indexes are available to assess histology more accurately in trials, and they may also be applicable to clinical practice. Additional interventional trials are now necessary to establish definitions of HR and its potential for disease modification.

Publication types

  • Systematic Review

MeSH terms

  • Aminosalicylic Acid / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Biological Products
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / pathology
  • Colitis, Ulcerative / physiopathology
  • Colon / pathology*
  • Gastrointestinal Agents / therapeutic use*
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Indans / therapeutic use
  • Janus Kinase Inhibitors / therapeutic use
  • Oxadiazoles / therapeutic use
  • Patient Care Planning*
  • Remission Induction
  • Sphingosine 1 Phosphate Receptor Modulators / therapeutic use
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors / therapeutic use*

Substances

  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Gastrointestinal Agents
  • Heterocyclic Compounds, 3-Ring
  • Indans
  • Janus Kinase Inhibitors
  • Oxadiazoles
  • Sphingosine 1 Phosphate Receptor Modulators
  • Tumor Necrosis Factor Inhibitors
  • upadacitinib
  • Aminosalicylic Acid
  • vedolizumab
  • ozanimod